Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.5 million","newsHeadline":"Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by ProgenaCare Global

    Menu

    ProgenaCare Global

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ProgenaCare Global

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+™ Antimicrobial Wound Gel

              Details:

              Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.

              Lead Product(s): Edetate Calcium Disodium,Sodium Citrate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Kane Biotech

              Deal Size: Undisclosed Upfront Cash: $0.5 million

              Deal Type: Agreement April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY